Drug intelligence / Profile preview

ATTO-005

Development stage: Unknown
Lead developer: Attovia Therapeutics
Modality: Antibody-Based Therapeutics

Overview

ATTO-005 is an investigational antibody drug developed by Attovia Therapeutics. It is currently in the discovery phase and is being explored for the treatment of immune system diseases, with a primary focus on inflammatory bowel diseases. The specific mechanism of action and molecular target have not been publicly disclosed as of June 2025. The drug represents part of Attovia's pipeline aimed at addressing immune-mediated disorders, leveraging advanced antibody engineering platforms[1][3].

Beyond the preview

Go deeper on ATTO-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATTO-005.

Explore the full profile